个人中心 - 老虎社区

泰然_4837

IP属地：未知

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 泰然_4837泰然_4837
  ·2024-10-16
  $京东(JD)$ 请了女拳冥灯代言，离死不远了…
  4,252 1
  12
  分享
  举报
- 泰然_4837泰然_4837
  ·2024-10-04
  $中国金融投资管理(00605)$ 谁说牛市不会破产[摊手]
  2,056 评论
  点赞
  分享
  举报
- 泰然_4837泰然_4837
  ·2020-10-14
  毫无惊喜…
  非常抱歉，此主贴已删除
  4,295 评论
  点赞
  分享
  举报
- 泰然_4837泰然_4837
  ·2020-02-05
  无偿提供援助，良心公司。
  吉利德：正在武汉开展两项临床试验，评估瑞德西韦有效性
  2月5日晚，吉利德科学就目前公众最关心的新冠肺炎潜在有效药物瑞德西韦的临床试验进展进行了回应。吉利德在发给媒体的邮件中表示，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床
  吉利德：正在武汉开展两项临床试验，评估瑞德西韦有效性
  4,205 评论
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3541331961763839","uuid":"3541331961763839","gmtCreate":1578237944798,"gmtModify":1578287762531,"name":"泰然_4837","pinyin":"tr4837tairan4837","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4dcf8ddec2c800c69aab986560a5f1e9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":22,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":"80.82%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":360638860263568,"gmtCreate":1729071914748,"gmtModify":1729073954544,"author":{"id":"3541331961763839","authorId":"3541331961763839","name":"泰然_4837","avatar":"https://static.tigerbbs.com/4dcf8ddec2c800c69aab986560a5f1e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3541331961763839","idStr":"3541331961763839"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$&nbsp;</a> 请了女拳冥灯代言，离死不远了…","listText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$&nbsp;</a> 请了女拳冥灯代言，离死不远了…","text":"$京东(JD)$ 请了女拳冥灯代言，离死不远了…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/360638860263568","isVote":1,"tweetType":1,"viewCount":4252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":356371691667768,"gmtCreate":1728006784979,"gmtModify":1728006981701,"author":{"id":"3541331961763839","authorId":"3541331961763839","name":"泰然_4837","avatar":"https://static.tigerbbs.com/4dcf8ddec2c800c69aab986560a5f1e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3541331961763839","idStr":"3541331961763839"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00605\">$中国金融投资管理(00605)$ </a> 谁说牛市不会破产[摊手]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/00605\">$中国金融投资管理(00605)$ </a> 谁说牛市不会破产[摊手]&nbsp;&nbsp;","text":"$中国金融投资管理(00605)$ 谁说牛市不会破产[摊手]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/356371691667768","isVote":1,"tweetType":1,"viewCount":2056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309831953,"gmtCreate":1602633660872,"gmtModify":1703827224316,"author":{"id":"3541331961763839","authorId":"3541331961763839","name":"泰然_4837","avatar":"https://static.tigerbbs.com/4dcf8ddec2c800c69aab986560a5f1e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3541331961763839","idStr":"3541331961763839"},"themes":[],"htmlText":"毫无惊喜…","listText":"毫无惊喜…","text":"毫无惊喜…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/309831953","repostId":"2075568923","repostType":4,"isVote":1,"tweetType":1,"viewCount":4295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":915499879,"gmtCreate":1580902554091,"gmtModify":1704342783445,"author":{"id":"3541331961763839","authorId":"3541331961763839","name":"泰然_4837","avatar":"https://static.tigerbbs.com/4dcf8ddec2c800c69aab986560a5f1e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3541331961763839","idStr":"3541331961763839"},"themes":[],"htmlText":"无偿提供援助，良心公司。","listText":"无偿提供援助，良心公司。","text":"无偿提供援助，良心公司。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/915499879","repostId":"1194953871","repostType":4,"repost":{"id":"1194953871","kind":"news","pubTimestamp":1580901840,"share":"https://www.laohu8.com/m/news/1194953871?lang=zh_CN&edition=full","pubTime":"2020-02-05 19:24","market":"us","language":"zh","title":"吉利德：正在武汉开展两项临床试验，评估瑞德西韦有效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1194953871","media":"澎湃新闻","summary":"2月5日晚，吉利德科学就目前公众最关心的新冠肺炎潜在有效药物瑞德西韦的临床试验进展进行了回应。吉利德在发给媒体的邮件中表示，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床","content":"<div>\n<p>2月5日晚，吉利德科学就目前公众最关心的新冠肺炎潜在有效药物瑞德西韦的临床试验进展进行了回应。吉利德在发给媒体的邮件中表示，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验，以确定瑞德西韦（Remdesivir）作为冠状病毒潜在治疗手段的安全性和有效性。其中一项研究评估Remdesivir用于确诊感染2019-nCoV且已住院但未表现出显著临床症状（如，需要额外吸氧...</p>\n\n<a href=\"https://www.thepaper.cn/newsDetail_forward_5798736\">网页链接</a>\n\n</div>\n","source":"pengpai_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德：正在武汉开展两项临床试验，评估瑞德西韦有效性</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德：正在武汉开展两项临床试验，评估瑞德西韦有效性\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-05 19:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.thepaper.cn/newsDetail_forward_5798736><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月5日晚，吉利德科学就目前公众最关心的新冠肺炎潜在有效药物瑞德西韦的临床试验进展进行了回应。吉利德在发给媒体的邮件中表示，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验，以确定瑞德西韦（Remdesivir）作为冠状病毒潜在治疗手段的安全性和有效性。其中一项研究评估Remdesivir用于确诊感染2019-nCoV且已住院但未表现出显著临床症状（如，需要额外吸氧...</p>\n\n<a href=\"https://www.thepaper.cn/newsDetail_forward_5798736\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","relate_stocks":{},"source_url":"https://www.thepaper.cn/newsDetail_forward_5798736","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194953871","content_text":"2月5日晚，吉利德科学就目前公众最关心的新冠肺炎潜在有效药物瑞德西韦的临床试验进展进行了回应。吉利德在发给媒体的邮件中表示，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验，以确定瑞德西韦（Remdesivir）作为冠状病毒潜在治疗手段的安全性和有效性。其中一项研究评估Remdesivir用于确诊感染2019-nCoV且已住院但未表现出显著临床症状（如，需要额外吸氧）的患者的治疗效果，另一项研究则评估Remdesivir用于出现较严重临床症状（如，需要吸氧）的确诊病患的疗效。这两项临床试验由中国研究人员牵头，均在武汉进行。吉利德无偿提供研究所需的药物，并为研究的设计和开展提供支持。瑞德西韦（Remdesivir）是一种在研的广谱抗病毒药物，尚未在全球任何国家获得批准。瑞德西韦（Remdesivir）在体外和体内动物模型中证明了对MERS和SARS病毒病原体的活性，它们也是冠状病毒，在结构上与2019-nCoV类似。针对MERS和SARS有限的临床前数据表明，Remdesivir可能对2019-nCoV具有潜在的活性。吉利德预计，临床试验的牵头研究单位将会在近期公布更多详细资料。公司也指出，需要注意的是，瑞德西韦（Remdesivir）是一种试验性药物，迄今为止仅有极少数感染2019-nCov的患者使用过，因此我们对其疗效尚无足够充分的了解，且目前不足以确保药物能被广泛使用。如果初步研究的结果表明Remdesivir治疗2019-nCoV感染的潜在安全性和有效性，我们会努力制定各种方案，通过适当的渠道将Remdesivir这种试验性药物向更多患者开放。我们也正与多家机构就未来临床试验的可能性进行讨论。在生产供应方面，吉利德还表示，为了应对近年来在西非爆发的埃博拉疫情，吉利德扩大了Remdesivir的生产，建立了产品库存应对未来的疾病大流行，同时也增加了制造Remdesivir的原材料库存。公司正在利用这部分库存满足“同情用药”的需求，以及目前计划在中国进行的两项临床试验的需求。”虽然尚未确定该药物是否可以安全有效地治疗2019-nCoV感染，但考虑到当前情况的紧迫性，我们正在采取多种措施加快生产进度，增加供应，包括拓展了外部制药合作伙伴网络，以加快原材料的采购，原料药和药品的生产；同时，我们开始在内部制造Remdesivir，以作为外部生产网络产能的补充。”吉利德表示。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":4205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}